- Global Pharma News & Resources

Enalare Therapeutics Nominated for Two Citeline Awards in Recognition of Outstanding Clinical Efforts

PRINCETON, N.J., March 8, 2023 ( - Enalare Therapeutics Inc., a clinical stage biopharmaceutical
company dedicated to developing novel compounds for the 
treatment of life-threatening critical care diseases and community health emergencies, announced today that it has been nominated for two prestigious Citeline Awards sponsored by Informa Pharma Intelligence in recognition of outstanding achievements in clinical research. Enalare is a finalist for the Most Successful Early Phase Research (Preclinical and Phase I) based on its breakthrough clinical study that demonstrates, for the first time, a drug's ability to reverse the hypoxic effect of propofol.  This was achieved with the company's lead compound, ENA-001, an agnostic respiratory stimulant. Furthermore, Enalare was also named along with its research partner organization, NEMA Research, Inc., as one of only four nominees for Best Clinical Partnership of the year. This award recognizes both innovative approaches and outstanding results in clinical research, for those who have developed important forms of clinical collaboration.

"It is a tremendous honor for Enalare to be a finalist for this very prestigious award as a recognition by leaders in the field of clinical trials that we have achieved something extraordinary," stated Joseph V. Pergolizzi, M.D., MBA, Head of Research and Development at Enalare. "Enalare has a novel drug candidate with many potential applications, all while facing the many challenges that start-up organizations have in today's highly competitive and evolving pharmacological market. I am proud of how our team has innovated, worked smarter, and developed methods that helped us excel while recognizing that we are a lean organization."

"Our partnership with NEMA Research, Inc. has been foundational to our success," continued Thomas Miller, Ph.D., Vice President of Clinical Development for Enalare. "NEMA understood not just our limitations as a start-up, but our potential as a company with a very important new product. They developed creative solutions to drive our research. It was their versatility combined with our product and vision that created powerful solutions, and we are honored to be recognized as a finalist for a CITELINE award for clinical trial partnership of the year."

The Citeline Awards, now in its 7th year, are given annually to honor large and small clinical research organizations for outstanding work. CITELINE's global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and med-tech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more. This year's award ceremony will be held on April 27, 2023, in Boston, Massachusetts.

About Enalare Therapeutics Inc.

Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life threatening critical care conditions and community based health emergencies, including post-operative respiratory depression, community drug overdose, and apnea of prematurity. Enalare plans to initiate additional clinical studies for ENA-001 across multiple indications in the near-term.

About ENA-001

Enalare's lead compound, ENA-001, is a one-of-a-kind new chemical entity (NCE) designed as an agnostic respiratory stimulant. The compound has a novel mechanism of action that affects ventilation via the peripheral chemoreceptor pathways in the carotid body. It utilizes the body's own ventilation control system to beneficially influence breathing and has been shown to be effective and well tolerated in five human studies to date. With its novel mechanism of action and based on findings to date, it could potentially improve the lives of those impacted by several life-threatening conditions, including community drug overdose, post-operative respiratory depression, and apnea of prematurity. ENA-001 is an investigational compound and is not approved for use by the FDA.

About NEMA Research

NEMA Research is a clinical research organization headquartered in Naples, Florida that works with global partners on a wide range of life sciences research projects.

# # #

Contact Information:
Morgan Wagner
Investor Relations

Original Source: Enalare Therapeutics Nominated for Two Citeline Awards in Recognition of Outstanding Clinical Efforts

Editor Details

  • Company:
    • Newswire
Last Updated: 08-Mar-2023